NEW THERAPEUTIC APPROACHES FOR PROSTATE CANCER

Prostate Cancer

<400,000 new cases diagnosed per year ~ 80,000 die from the disease

Unmet needs,o Biomarkers for the early diagnosis of clinically

significant prostate cancero Therapies for locally advanced – and metastatic

prostate cancer

Result of long-standing collaboration

PRO-NET

PRO-NET Consortium

Ecomomic perspective

Sales forcast prostate cancer therapy2016 2020

Patients 150.000 150.000Market share 15% 50%Treated patients 22,500 75,000Treatment cost 20,000 16,000Revenues of distributor 450 1,200Revenues Newco 45 120

• Prostate cancer market is very large and lucrative• Multiple marker approach enhances the chances of succes• Economic potential is extremely high when significant is made

The chances of external (VC) funding is very high

Preconditions for succes

Chances of failure are reduced by developing drugs against several targets,

However:

• Founding an independent company is essential (not Skyline or Noviogendix)

• Install management including external new manager(initially Schalken, CSO and Viëtor, CEO)

• Secure IP position• Design development plan (including regulatory affairs)• Write and implement business plan

VC funding